ALX Oncology Holdings Inc.
ALXO
$2.11
-$0.07-3.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.39% | 3.30% | -8.39% | -13.72% | -8.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.39% | -22.36% | -16.33% | 3.50% | 30.97% |
| Operating Income | 34.39% | 22.36% | 16.33% | -3.50% | -30.97% |
| Income Before Tax | 32.00% | 21.77% | 16.14% | -3.55% | -31.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.00% | 21.77% | 16.14% | -3.50% | -31.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.00% | 21.77% | 16.14% | -3.50% | -31.50% |
| EBIT | 34.39% | 22.36% | 16.33% | -3.50% | -30.97% |
| EBITDA | 34.55% | 22.48% | 16.43% | -3.43% | -30.94% |
| EPS Basic | 39.60% | 33.43% | 30.38% | 16.44% | -13.85% |
| Normalized Basic EPS | 41.24% | 33.43% | 30.37% | 16.40% | -13.90% |
| EPS Diluted | 39.60% | 33.43% | 30.38% | 16.44% | -13.85% |
| Normalized Diluted EPS | 41.24% | 33.43% | 30.37% | 16.40% | -13.90% |
| Average Basic Shares Outstanding | 10.52% | 16.31% | 20.69% | 24.44% | 17.68% |
| Average Diluted Shares Outstanding | 10.52% | 16.31% | 20.69% | 24.44% | 17.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |